Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Milon M is an over-the-counter (OTC) composite gastrointestinal medicine developed and manufactured by Teika Pharmaceutical in Japan. It is formulated as an oral powder containing 14 active ingredients, including antacids (sodium bicarbonate and magnesium carbonate), digestive enzymes (biodiastase 1000 and prozyme), mucosal protective agents (sodium copper chlorophyllin and glycyrrhiza powder), a choleretic agent (ursodeoxycholic acid), and various herbal stomachics (cinnamon bark, turmeric, fennel, gentian, clove, and ginger). Milon M is indicated for the relief of gastrointestinal symptoms such as hyperacidity, heartburn, stomach discomfort, abdominal bloating, indigestion, nausea, vomiting, stomachache, and loss of appetite.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Milon M.